Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $7.4600 (3.32%) ($7.1500 - $7.5700) on Thu. Mar. 28, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.36% (three month average) | RSI | 72 | Latest Price | $7.4600(3.32%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.3% a day on average for past five trading days. | Weekly Trend | TGTX advances 2.8% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(58%) ARKK(57%) IWO(57%) | Factors Impacting TGTX price | TGTX will decline at least -2.68% in a week (0% probabilities). VXX(-16%) UUP(-11%) TLT(-9%) VIXM(-8%) IFRA(-5%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.68% (StdDev 5.36%) | Hourly BBV | 0 () | Intraday Trend | 3% | | | |
|
5 Day Moving Average | $7.18(3.9%) | 10 Day Moving Average | $7.25(2.9%) | 20 Day Moving Average | $6.97(7.03%) | To recent high | 0% | To recent low | 43.7% | Market Cap | $945m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |